Core Viewpoint - BGM Group's stock price increased by 7.53% to $8.00 per share, with a market capitalization of $1.472 billion as of August 13 [1] Financial Performance - As of March 31, 2025, BGM Group reported total revenue of $14.3114 million, representing a year-on-year growth of 13.92% [1] - The net profit attributable to the parent company was -$0.8612 million, showing a significant decrease of 307.79% year-on-year [1] Company Overview - BGM Group, formerly known as Qilian International Holdings Group, is headquartered in Chengdu, China, and focuses on the biopharmaceutical, bio-extraction, and healthcare sectors [1] - The company's product range includes tetracycline raw materials, licorice preparations, and crude heparin sodium [1] - Tetracycline raw materials are used for producing human antibiotics and support global poultry and aquaculture industries [1] - Crude heparin sodium is processed into refined heparin sodium and injectable heparin sodium solutions, serving as a major anticoagulant [1] - Licorice preparations, such as compound licorice tablets, are used as cough remedies and supplied to retail pharmacies [1]
博美集团上涨7.53%，报8.0美元/股，总市值14.72亿美元